Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131.
Wanda L SalzerMichael J BurkeMeenakshi DevidasSi ChenLia GoreEric C LarsenMichael BorowitzBrent WoodNyla A HeeremaAndrew J CarrollJoanne M HildenMignon L LohElizabeth A RaetzNaomi J WinickWilliam L CarrollStephen P HungerPublished in: Cancer (2017)
In AALL1131, CLOF, administered with CPM and ETOP, was associated with unacceptable toxicity. Cancer 2018;124:1150-9. © 2017 American Cancer Society.